Big Money’s Pro-Techne Corp (NASDAQ:TECH) Sentiment In 2018 Q1, now at 1.32

June 29, 2018 - By Rhonda Roth

Bio-Techne Corporation (NASDAQ:TECH) Corporate Logo

Positions for Techne Corp (NASDAQ:TECH)

“Big money sentiment for Techne Corp (NASDAQ:TECH) in 2018 Q1 increased to 1.32, SEC.gov filings reveal. That’s up 0.34, from 2017Q4’s 0.98. 136 institutional investors increased and started new stock positions, while 103 trimmed and sold equity positions in Techne Corp so the sentiment has improved. These funds own 35.01 million shares, that’s down from 35.53 million shares in 2017Q4. Funds holding Techne Corp in top 10 increased from 2 to 4 for an increase of 2. 14 Investors Sold All; 89 Reduced Holdings; 83 increased holdings while 53 institutional investors bought holdings.

Largest Techne Corp Investors

Sandhill Capital Partners Llc owns 150,946 shares in Techne Corp as of 2018 Q1. Techne Corp’s shareholder Brown Capital Management Llc owns 1.99 million shares as of 2018 Q1. Summit Creek Advisors Llc reported 119,419 shares. Stone Run Capital Llc revealed 37,325 shares position in Techne Corp. The Minnesota-based fund Mairs & Power Inc holds 1.38 million shares or 2.57% of their US long stock exposure.

Bio-Techne Corporation, together with its subsidiaries, develops, makes, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide.The company has $5.55 billion market cap. It operates through three divisions: Biotechnology, Protein Platforms, and Diagnostics.The P/E ratio is 49.89. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.

The stock increased 0.36% or $0.53 during the last trading session, touching $147.66.Bio-Techne Corporation has volume of 69,650 shares. Since June 29, 2017 TECH has risen 33.83% and is uptrending. The stock outperformed the S&P500 by 21.26%.

Earnings report for Bio-Techne Corporation (NASDAQ:TECH) is awaited on August, 14., according to RTT. The earnings per share diference is $0.16 or 15.69 % up from last years number. Previous year: $1.02; Analysts forcast: $1.18. In case of $1.18 earnings per share TECH’s profit could hit $44.34 million. 4.42 % EPS growth is what analysts predict. $1.13 earnings per share was reported for previous quarter.

Denver Investment Limited Liability Co accumulated 1% or 125,533 shs. Moreover, Commonwealth Of Pennsylvania School Empls Retrmt System has 0.02% invested in Bio-Techne Corporation (NASDAQ:TECH). Zeke Cap Limited Liability Company has invested 0.18% of its capital in Bio-Techne Corporation (NASDAQ:TECH). Citigroup stated it has 0% of its capital in Bio-Techne Corporation (NASDAQ:TECH). Credit Suisse Ag invested in 0.01% or 41,759 shs. Lord Abbett And Limited reported 321,376 shs stake. Comml Bank Of New York Mellon invested in 0.02% or 509,020 shs. Eaton Vance Mngmt owns 6,016 shs for 0% of their capital. Comerica Bank & Trust reported 0.04% of its capital in Bio-Techne Corporation (NASDAQ:TECH). Jefferies Gp holds 0.1% or 9,270 shs in its capital. Amalgamated Bancorp reported 8,280 shs. Moreover, Macquarie Group has 0.05% invested in Bio-Techne Corporation (NASDAQ:TECH). Ing Groep Nv reported 0.01% of its capital in Bio-Techne Corporation (NASDAQ:TECH). Bnp Paribas Arbitrage Sa invested 0% of its capital in Bio-Techne Corporation (NASDAQ:TECH). Chicago Equity Prns Limited Liability Com reported 0.01% in Bio-Techne Corporation (NASDAQ:TECH).

Bio-Techne Corporation had 3 insider sales and 0 buys since February 13, 2018. This’s net activity of $2.13 million. Eansor Norman David also sold $164,932 worth of Bio-Techne Corporation (NASDAQ:TECH) shs. Kummeth Charles R. also sold $1.28M worth of Bio-Techne Corporation (NASDAQ:TECH) on Thursday, June 7.

Bio-Techne Corporation (NASDAQ:TECH) Ratings Coverage

In total 6 analysts cover Bio-Techne Corporation (NASDAQ:TECH). “Buy” rating has 4, “Sell” are 0, while 2 are “Hold”. 67% are bullish. 9 are the (NASDAQ:TECH)’s analyst reports since January 18, 2018 according to StockzIntelligence Inc. In Thursday, May 3 report Leerink Swann maintained the stock with “Buy” rating. On Tuesday, February 6 the firm earned “Buy” rating by Robert W. Baird. On Thursday, May 3 the firm has “Buy” rating given by Deutsche Bank. On Wednesday, June 27 the rating was downgraded by Deutsche Bank to “Hold”. On Thursday, March 1 the stock has “Buy” rating by Deutsche Bank. On Wednesday, February 7 the rating was maintained by Craig Hallum with “Buy”. On Thursday, January 18 the firm has “Buy” rating given by Robert W. Baird. On Wednesday, February 7 the rating was maintained by Stephens with “Hold”.

For more Bio-Techne Corporation (NASDAQ:TECH) news released recently go to: Realmoney.Thestreet.com, Investingnews.com, Streetinsider.com, Investingnews.com or Investingnews.com. The titles are as follows: “Jim Cramer: Tech Can’t Do it All Alone” released on June 05, 2018, “Blockchain Opportunities to Surpass US$2.5 Trillion, Report Says” on June 28, 2018, “Bio-Techne (TECH) to Acquire Quad Technologies” with a publish date: June 07, 2018, “OEM Pay Users to Reach 450 Million by 2020, Apple Pay Leads” and the last “JA Solar Supplies Half-Cell Modules for Solar Plant in Africa” with publication date: June 29, 2018.

Bio-Techne Corporation (NASDAQ:TECH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: